Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Accumulated Depreciation (2019 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Accumulated Depreciation for 7 consecutive years, with $20.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Accumulated Depreciation changed N/A to $20.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $20.1 million, a N/A change, with the full-year FY2024 number at $16.6 million, up 39.0% from a year prior.
  • Accumulated Depreciation was $20.1 million for Q3 2025 at 4D Molecular Therapeutics, up from $18.8 million in the prior quarter.
  • In the past five years, Accumulated Depreciation ranged from a high of $20.1 million in Q3 2025 to a low of $4.6 million in Q2 2021.
  • A 5-year average of $11.8 million and a median of $11.9 million in 2023 define the central range for Accumulated Depreciation.
  • Peak YoY movement for Accumulated Depreciation: skyrocketed 49.68% in 2024, then soared 34.56% in 2025.
  • 4D Molecular Therapeutics' Accumulated Depreciation stood at $5.3 million in 2021, then increased by 26.08% to $6.7 million in 2022, then skyrocketed by 77.72% to $11.9 million in 2023, then surged by 39.0% to $16.6 million in 2024, then increased by 20.97% to $20.1 million in 2025.
  • Per Business Quant, the three most recent readings for FDMT's Accumulated Depreciation are $20.1 million (Q3 2025), $18.8 million (Q2 2025), and $17.6 million (Q1 2025).